Determining genetic signature of lung tumors can help guide treatment

May 20, 2008

The first U.S. clinical trial using genetic screening to identify lung tumors likely to respond to targeted therapies supports the use of those drugs as first-line treatment rather than after standard chemotherapy has failed. While the study led by Massachusetts General Hospital Cancer Center investigators found that upfront gefitinib (Iressa) treatment considerably improved the outcomes for non-small-cell-lung-cancer (NSCLC), additional research is required before such a strategy can be used for routine treatment planning. The report appears in the May 20 Journal of Clinical Oncology.

“This is a pivotal clinical trial that demonstrates the power of personalized medicine in lung cancer treatment,” says Lecia Sequist, MD, MPH, of the MGH Cancer Center, who led the study. “It is an exciting glimpse into what we hope is the future of cancer care. Instead of a ‘one size fits all’ therapy, we are moving towards finding the best treatment for each patient.”

The most common form of lung cancer, NSCLC is the leading cause of cancer deaths in the U.S. Until recently, there were no treatment options for NSCLC patients in whom chemotherapy failed. Iressa, which disables the epidermal growth factor receptor (EGFR) on the surface of lung cancer cells, was approved in 2003 for treatment of NSCLC even though it shrank tumors in less than 15 percent of patients because, in those whom it did help, responses were rapid and dramatic.

In 2004 MGH Cancer Center researchers and a team from Dana-Farber Cancer Institute both discovered why Iressa’s success was confined to a limited group of patients. Specific EGFR mutations that were probably responsible for a tumor’s development also made the cancer sensitive to Iressa treatment. Subsequent to that announcement, the Laboratory for Molecular Medicine at the Harvard-Partners Center for Genetics and Genomics developed a test to screen for these sensitizing mutations.

Late in 2004 a collaborative group led by MGH investigators began the current study, designed to see whether using Iressa as an initial treatment for patients with a sensitizing EGFR mutation would improve treatment results. Out of 98 NSCLC patients screened at 11 centers – including the MGH Cancer Center and DFCI – over a two-year period, 34 had a sensitizing mutation. Of those, 31 entered the trial and began receiving daily oral doses of Iressa instead of standard chemotherapy. Iressa treatment continued indefinitely unless significant side effects occurred or tumor growth continued or resumed.

All but two of the participants responded positively to Iressa treatment, with their tumors either shrinking significantly or not growing for a month or longer. At the end of the study period, 14 patients had died but 17 remained alive. The overall survival rate and the length of time until participants’ tumors resumed growing were two or three times greater than would be expected with standard chemotherapy, Sequist explains. Only one participant dropped out because of treatment side effects.

The current study also analyzed the specific EGFR mutations in participants’ tumors to see if there were differences in the response to treatment. Patients with the two most typical mutations had vigorous responses to Iressa, but the seven patients found to have atypical mutations had a more limited response. None of the atypical cases had tumor shrinkage, but the majority had disease stabilization for a period of time. Two patients who experienced rapid regrowth of their cancers were found to have additional EGFR mutations that previous research had indicated conferred resistance to the drug. It has been theorized that those resistance mutations develop in response to treatment, but this is the first observation of the mutations’ being present before treatment began.

“It’s starting to look like the strategy of genomically-directed cancer therapy will need to incorporate testing for multiple genotypes – screening for three, four or even more genetic markers, some of which may indicate likelihood of response to treatment, and others the chance of resistance,” says Sequist. “We think these results will also apply to other effective EGFR inhibitors, and we hope they can be duplicated for other types of cancer that involve these mutations. But what is needed next is a larger-scale, randomized clinical trial comparing an EGFR blocker with standard therapy in a genotype-selected population.” Sequist is an instructor in Medicine at Harvard Medical School.

Although Iressa is currently not being marketed in the U.S., the trial reported in this article was supported by AstraZeneca, the drug’s manufacturer. Several other EGFR inhibitors, including Tarceva (erlotinib), are either on the market or in clinical trials.

Source: Massachusetts General Hospital

Explore further: Drug yields high response rates for lung cancer patients with harsh mutation

Related Stories

Drug yields high response rates for lung cancer patients with harsh mutation

October 18, 2017
A targeted therapy resurrected by the Moon Shots Program at The University of Texas MD Anderson Cancer Center has produced unprecedented response rates among patients with metastatic non-small cell lung cancer that carries ...

Exercise interventions in advanced lung cancer patients led to increased functionality

October 18, 2017
Physical exercise and psycho-social interventions in patients with advanced stage lung cancer improved functional capacity, which may be linked to quality of life benefits. Dr. Quist of the University of Copenhagen in Denmark ...

Researchers identify novel therapeutic strategy for drug-resistant thyroid cancers

October 18, 2017
Perhaps the only thing more devastating than being diagnosed with cancer is to find out after a period of remission that the cancer has become drug-resistant and progressed to an incurable state. This is the unfortunate fate ...

Ultra-personal therapy: Gene tumor boards guide cancer care

October 18, 2017
Doctors were just guessing a decade ago when they gave Alison Cairnes' husband a new drug they hoped would shrink his lung tumors. Now she takes it, but the choice was no guesswork. Sophisticated gene tests suggested it would ...

From Dr. Jekyll to Mr. Hyde of cancer immunotherapy

October 18, 2017
Novel immunotherapies can strengthen the body's own defenses against cancer cells. Treatment of patients with advanced disease can promote partial and complete tumor regressions. However, such strategies also frequently fail. ...

Clinical trial hopes to provide less toxic treatment for prostate cancer

October 18, 2017
Over the last decade, immunotherapy has emerged as one of the most promising and innovative fields in oncology. The goal of immunotherapy is to help a patient's own immune system fight cancer. A major breakthrough came in ...

Recommended for you

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

Mutant gene found to fuel cancer-promoting effects of inflammation

October 19, 2017
A human gene called p53, which is commonly known as the "guardian of the genome," is widely known to combat the formation and progression of tumors. Yet, mutant forms of p53 have been linked to more cases of human cancer ...

New study reveals breast cancer cells recycle their own ammonia waste as fuel

October 19, 2017
Breast cancer cells recycle ammonia, a waste byproduct of cell metabolism, and use it as a source of nitrogen to fuel tumor growth, report scientists from Harvard Medical School in the journal Science.

Breast cancer researchers find bacteria imbalance link

October 19, 2017
Researchers in the United States have uncovered differences in the bacterial composition of breast tissue of healthy women versus those with breast cancer.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

gdpawel
not rated yet Jun 23, 2008
What do you do when there are too many receptors and the cancer cell still continues to grow and divide?

When considering a 'targeted' cancer drug which is believed to act only upon cancer cells that have a specific genetic defect, it is useful to know if a patient's cancer cells do or do not have precisely that defect. Although presence of a 'targeted' defect does not necessarily mean that a drug will be effective, absence of the targeted defect may rule out use of the drug.

Cancer cells have many mutations in many different pathways, so even if one route or two is shut down by a targeted treatment, the cancer cell may be able to use other routes. Targeted drugs have not been accompanied by reliable, specific predictive tests allowing for rational and economical use of these drugs. Molecular diagnostics approved often have been mostly or totally ineffective at identifying clinical responders to the various therapies.

Gene-based testing examines a single process within the cell or a relatively small number of processes. The aim is to tell if there is a theoretical predispostion to drug response.

Gene-based testing involves the use of dead, formaldehyde preserved cells that are never exposed to 'targeted' drugs. Gene-based tests cannot tells us anything about uptake of a certain drug into the cell or if the drug will be excluded before it can act or what changes will take place within the cell if the drug successfully enters the cell.

Gene-based tests cannot discriminate among the activities of different drugs within the same class. Instead, it assumes that all drugs within a class will produce precisely the same effect, even though from clinical experience, this is not the case. Nor can Gene-based tests tell us anything about drug combinations.

If you find one or more implicated genes in a patient%u2019s tumor cells, how do you know if they are functional (is the encoded protein actually produced?). If the protein is produced, is it functional? If the protein is functional, how is it interacting with other functional proteins in the cell?

Are you sure that you%u2019ve identified every single protein that might influence sensitivity or resistance to these drugs? The "cell" is a system, an integrated, interacting network of genes, proteins and other cellular constituents that produce functions. You need to analyze the systems' response to drug treatments, not just one or a few targets or pathways.

There are many mechanisms/pathways to altered cellular function. Functional profiling measures what happens at the end, rather than the status of the individual mechanisms/pathways. Cancer is a complex disease and needs to be attacked on many fronts.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.